

MELANOMA SAMPLES

Percentage of *BRAF* V600E mutation obtained by pyrosequencing

475 samples from 428 patients. All consecutive samples with stage III or IV melanomas received in Ambroise Paré hospital pathology department from March 2010 to May 2014

→ 368 samples with at least 80% of tumor cells of whom 142 with *BRAF* V600E



Fluorescence *in situ* hybridization (FISH) with *BRAF* (RP11-129G9 BAC)/chromosome 7 centromere probes

141 melanoma samples available on TMA (140 patients)
16 not interpretable because of lack of tumor on TMA sections, high lymphocytic infiltration or high background fluorescent signals.

→ 125 samples with interpretable results

59 *BRAF* WT

56 *BRAF* V600E

10 with another *BRAF* exon 15 mutations (V600K n=7, K601E n=2, 600-601delinsE n=1).

→ 44 samples analyzed with another *BRAF* probe (SureFISH 7q34 *BRAF*)



Single nucleotide polymorphism (SNP) array analysis

18 frozen samples available

→ 17 samples with FISH results

→ 1 sample with non interpretable FISH result

MELANOCYTIC NEVI (dermic and/or junctional)

FISH with *BRAF* (RP11-129G9 BAC)/chromosome 7 centromere probes and immunohistochemistry (IHC) with VE1 antibody

→ 42 samples from 42 patients



IHC

→ 42 samples interpretable

9 *BRAF* p.V600E negative

33 *BRAF* p.V600E positive



FISH analysis

→ 33 samples with interpretable FISH results

6 *BRAF* p.V600E negative

27 *BRAF* p.V600E positive

9 FISH not interpretable because of lack of tumor on TMA sections